Table 2.

In vivo efficacy analysis of theranostic nanomedicines.

Type of theranostic nanomedicine	Targeting/Therapeutic/ Diagnostic agent	Site of administration	Duration of diagnosis	Duration of therapy	Fold of efficacy enhancement	Reference
Drug-polymer conjugates	RGD/64Cu	i.v.	3 h	3 h	~ 1 fold in tumor	39
Polymeric nanoparticles	Passive/Quantum dots/Iron oxide nanoparticles	i.v.	6 h	--	~ 1.5 folds in tumor	18
Magnetic nanoparticles	Cy 5.5/siRNA/ Iron oxide nanoparticles	i.v.	48 h	48 h	In vivo silencing in tumor was observed	60
Solid lipid nanoparticles	RGD/Lead selenide	i.v.	120 h	--	~ 1 fold in tumor vasculature	66
Dendrimers	LHRH/ Phthalocyanines	i.v.	10 h	24 h	Significant fluorescent was observed in tumor with cytotoxicity	75
Liposomes	Passive/Camptothecin/Irinotecan/ Cholesterol	Intratumoral	24 h	24 h	~ 6 folds longer duration of detection/more drug concentration at tumor site	90
Micelles	Passive/Iron oxide nanoparticles	i.v.	24 h	24 h	~ 1fold T2 value decreases with significant cell death	108
Carbon nanomaterials	Folic acid/MWCNTs/ Technitium-99m	i.v.	24 h	1-15 days (2 doses per week)	~ 8.5 folds higher than non- targeted MWCNTs after 24 h of diagnosis with at least ~ 2 folds higher tumor inhibition	132